Bevacizumab trials for Lung cancer

All Bevacizumab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Bevacizumab for Lung cancer

• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
  NCT06839105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
  NCT05654454 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
  NCT06775275 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
  NCT06131840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
  NCT06265350 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
  NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
  NCT06663306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
  NCT05503667 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
  NCT03872661 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
  NCT07001618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 603 locations
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
  NCT04973293 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
  NCT05588388 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 3 locations
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
  NCT05468242 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  NCT05005403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations

Common questions

How many trials study Bevacizumab for Lung cancer?

21 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.